VCEL
What one share of Vericel holds
Biological Products, (No Diagnostic Substances)
Vericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn care markets. We have a highly differentiated portfolio of cell therapy and specialty biologic products that combines innovations in biology with medical technologies.
Vericel’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $5.83 |
|---|---|
| Profit | $0.46 |
| Capex (buildings and equipment) | $0.15 |
| Free cash flow | $1.17 |
| Cash and investments | $2.45 |
| Book value | $7.23 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $2.35 | −$1.18 | $0.06 | −$0.92 | — | $0.78 |
| 2017 | $1.92 | −$0.52 | $0.05 | −$0.44 | — | $0.63 |
| 2018 | $2.26 | −$0.20 | $0.07 | −$0.08 | — | $2.35 |
| 2019 | $2.67 | −$0.22 | $0.06 | −$0.22 | — | $2.48 |
| 2020 | $2.63 | $0.06 | $0.06 | $0.32 | — | $2.93 |
| 2021 | $3.36 | −$0.16 | $0.17 | $0.45 | — | $3.64 |
| 2022 | $3.49 | −$0.35 | $0.16 | $0.21 | — | $4.07 |
| 2023 | $4.15 | −$0.07 | $0.42 | $0.32 | — | $4.72 |
| 2024 | $4.59 | $0.20 | $1.24 | −$0.11 | — | $5.88 |
| 2025 | $5.30 | $0.32 | $0.52 | $0.47 | — | $7.01 |